Literature DB >> 19184328

The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations.

Beata Zalewska-Szewczyk1, Agnieszka Gach, Krystyna Wyka, Jerzy Bodalski, Wojciech Młynarski.   

Abstract

Repeated administration of L-asparaginase leads to the development of specific antibodies and hypersensitivity reactions. The aim of the study was to evaluate a possible cross-reaction of anti-asparaginase antibodies, developed against the native E. coli L-asparaginase (Asparaginase Medac), with other preparations of the enzyme. Sixteen patients with acute lymphoblastic leukemia, in whom in the reinduction phase of treatment hypersensitivity against L-asparaginase was observed and/or the presence of anti-asparaginase antibodies was established were recruited for the present study. Ten out of 16 tested sera showed cross-immunoreactivity to PEG-asparaginase, while no reactivity to L-asparaginase derived from Erwinia chrysantemi was observed. Since cross-reacting antibodies were also found in sera of patients with no overt allergic reaction, L: -asparaginase may undergo silent inactivation during the reinduction phase of therapy. This finding is of clinical importance with regard to appropriate dosage and necessitates careful enzyme activity monitoring in all patients undergoing repeated treatment with various L-asparaginase preparations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184328     DOI: 10.1007/s10238-008-0026-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  18 in total

Review 1.  Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.

Authors:  Umesh K Narta; Shamsher S Kanwar; Wamik Azmi
Journal:  Crit Rev Oncol Hematol       Date:  2006-10-02       Impact factor: 6.312

2.  Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.

Authors:  Y Kamisaki; H Wada; T Yagura; A Matsushima; Y Inada
Journal:  J Pharmacol Exp Ther       Date:  1981-02       Impact factor: 4.030

3.  Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.

Authors:  H J Müller; L Löning; A Horn; D Schwabe; M Gunkel; M Schrappe; V von Schütz; G Henze; J Casimiro da Palma; J Ritter; J P Pinheiro; M Winkelhorst; J Boos
Journal:  Br J Haematol       Date:  2000-08       Impact factor: 6.998

4.  Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.

Authors:  Michel Duval; Stefan Suciu; Alina Ferster; Xavier Rialland; Brigitte Nelken; Patrick Lutz; Yves Benoit; Alain Robert; Anne-Marie Manel; Etienne Vilmer; Jacques Otten; Noël Philippe
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

5.  Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.

Authors:  T Yoshimoto; H Nishimura; Y Saito; K Sakurai; Y Kamisaki; H Wada; M Sako; G Tsujino; Y Inada
Journal:  Jpn J Cancer Res       Date:  1986-12

6.  Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.

Authors:  A Abuchowski; G M Kazo; C R Verhoest; T Van Es; D Kafkewitz; M L Nucci; A T Viau; F F Davis
Journal:  Cancer Biochem Biophys       Date:  1984-06

7.  Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.

Authors:  N K Cheung; I Y Chau; P F Coccia
Journal:  Am J Pediatr Hematol Oncol       Date:  1986

8.  An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.

Authors:  L J Ettinger; J Kurtzberg; P A Voûte; H Jürgens; S L Halpern
Journal:  Cancer       Date:  1995-03-01       Impact factor: 6.860

Review 9.  Use of L-asparaginase in childhood ALL.

Authors:  H J Müller; J Boos
Journal:  Crit Rev Oncol Hematol       Date:  1998-08       Impact factor: 6.312

10.  Factors which may influence the effectiveness of L-asparaginases as tumor inhibitors.

Authors:  J D Broome
Journal:  Br J Cancer       Date:  1968-09       Impact factor: 7.640

View more
  20 in total

1.  The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.

Authors:  Troy Z Horvat; Joshua J Pecoraro; Ryan J Daley; Larry W Buie; Amber C King; Raajit K Rampal; Martin S Tallman; Jae H Park; Dan Douer
Journal:  Leuk Res       Date:  2016-08-26       Impact factor: 3.156

Review 2.  What makes a good new therapeutic L-asparaginase?

Authors:  Angela Beckett; David Gervais
Journal:  World J Microbiol Biotechnol       Date:  2019-09-24       Impact factor: 3.312

3.  Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase.

Authors:  Wing H Tong; Rob Pieters; Wim J E Tissing; Inge M van der Sluis
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

4.  A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

Authors:  Wing H Tong; Rob Pieters; Gertjan J L Kaspers; D Maroeska W M te Loo; Marc B Bierings; Cor van den Bos; Wouter J W Kollen; Wim C J Hop; Claudia Lanvers-Kaminsky; Mary V Relling; Wim J E Tissing; Inge M van der Sluis
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

5.  Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.

Authors:  L N Ramya; Krishna Kanth Pulicherla
Journal:  Pathol Oncol Res       Date:  2015-03-06       Impact factor: 3.201

6.  Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.

Authors:  Rachel E Rau; ZoAnn Dreyer; Mi Rim Choi; Wei Liang; Roman Skowronski; Krishna P Allamneni; Meenakshi Devidas; Elizabeth A Raetz; Peter C Adamson; Susan M Blaney; Mignon L Loh; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2017-11-01       Impact factor: 3.167

Review 7.  L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.

Authors:  Rob Pieters; Stephen P Hunger; Joachim Boos; Carmelo Rizzari; Lewis Silverman; Andre Baruchel; Nicola Goekbuget; Martin Schrappe; Ching-Hon Pui
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

Review 8.  Overview of the structure, side effects, and activity assays of l-asparaginase as a therapy drug of acute lymphoblastic leukemia.

Authors:  Nanxiang Wang; Wenhui Ji; Lan Wang; Wanxia Wu; Wei Zhang; Qiong Wu; Wei Du; Hua Bai; Bo Peng; Bo Ma; Lin Li
Journal:  RSC Med Chem       Date:  2022-01-12

9.  Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.

Authors:  Richard H Ko; Tamekia L Jones; David Radvinsky; Nathan Robison; Paul S Gaynon; Eduard H Panosyan; Ioannis A Avramis; Vassilios I Avramis; Joan Rubin; Lawrence J Ettinger; Nita L Seibel; Girish Dhall
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

Review 10.  Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase.

Authors:  Nicolas Boissel; Leonard S Sender
Journal:  J Adolesc Young Adult Oncol       Date:  2015-09       Impact factor: 2.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.